Home / Innere Medizin / Onkologie / AACR 2019: Novel therapeutic approach for vulnerable patients with esophageal cancer

Clinical Trial

AACR 2019: Novel therapeutic approach for vulnerable patients with esophageal cancer

The experimental oncolytic adenovirus telomelysin (OBP-301) in combination with radiotherapy was safe and showed early clinical efficacy in vulnerable patients with esophageal cancer. This a phase I trial presented at the AACR 2019 Annual Meeting shows.

The oncolytic adenovirus telomelysin (OBP-301) is an attenuated adenovirus which contains the human telomerase reverse transcriptase (hTERT) promoter to regulate viral replication. Infection with telomelysin causes cell lysis in various cancer cells.

So profitieren Sie von medonline.ch

  • eLearnings, Literaturstudien
  • Aktuelle Fachartikel, State-of-the-Art-Beiträge, Kongressberichte, Experteninterviews
  • Produktfortbildung

 

Melden Sie sich jetzt an & und bleiben Sie top-informiert!

LOGIN